United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which could help establish it as the new standard treatment for the condition. Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK.

Pfizer's drug for advanced lung cancer shows promising long-term trial results

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After five years of median follow-up, median progression-free survival (PFS) based on investigator a.

Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, the regulator said on Friday.

EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder

Pfizer's dividend yield is rising as the stock price is falling.

Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?

BioNTech SE

Moderna

A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.

New U.S. bird-flu case is first with respiratory symptoms, CDC says

Johnson & Johnson

Merck

CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.

Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference

British American Tobacco

Enbridge

Kinder Morgan

Realty Income Corp

Vici Properties

Verizon

Markets spooked by the Fed's language on inflation progress, causing uncertainty on rate cuts. Dividend Harvesting Portfolio retraces slightly but still generates respectable dividend income. Portfolio composition shows diversification and focus on sustainable dividend income.

Dividend Harvesting Portfolio Week 169: $16,900 Allocated, $1,503.06 In Projected Dividends

Flex Lng Ltd

Altria

Rio Tinto plc Sponsored

AT&T

Vale S.A.

The stock market is not all about buying high-flying stocks that can be potential 10-baggers or 20-baggers. While growth stocks should be a part of the portfolio, it's low-beta dividend stocks that serve as a pillar of strength for the portfolio.

Steady Gains, Solid Yields: 7 Low-Beta Stocks Paying 5%+ Dividends

Arvinas Inc

Axsome Therapeutics

Cytokinetics

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Viking Therapeutics

Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

Advanced Micro Devices

Intel

Oaktree Specialty Lending

PayPal

Starbucks

Seven firms representing various industries stand out as prospective high-yielders as the market approaches H2 2024. Each one has distinct development drivers and value propositions.

7 Must-Own Stocks to Hold for the Second Half of 2024

General Motors

Everyone loves discounts and that's essentially what value stocks to buy represent. The difference, though, between a value play and a “cheap” security comes down to the credibility (or lack thereof) of the underlying narrative.

If You Can Only Buy One Value Stock in May, It Better Be One of These 3 Names

Boeing

WallStreetBets is renowned as a group focused on making some of the riskiest bets in the market. I usually scour the market for high-risk, high-reward bets.

Revenge of the Apes: 3 Reddit WallStreetBets Stocks That Could Pop Next

Ares Capital

Main Street Capital

There are numerous stocks with safe and attractive high yields. There are several of them that we are avoiding right now, including a few that we recently sold. We share five that we are avoiding right now and also list a few that we are buying.

Five 6-9% Low-Risk Yields To Avoid In May 2024

Walgreens

Investors looking for dividend stocks have probably noticed Pfizer and Walgreens Boots Alliance offer above-average yields. Walgreens Boots Alliance stock is under pressure after shutting down an initiative that would have made it more than just a retail pharmacy chain.

2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?

Coca-Cola

Morgan Stanley

There is no joy like receiving passive income each quarter. I am someone who loves to receive dividend income and see my money grow without having to do anything.

Dividend Deals: 3 Overlooked Stocks Offering Incredible Value

A monthly chart of PFE using Worden's TC2000 Gold shows the stock oversold on a monthly basis. A stock with a 5.8-6% dividend yield in today's market immediately draws attention. Is the dividend sustainable, and will the pharma giant be able to sustain the current $0.42 per quarter ($1.68 per year) dividend pace and also continue to boost that dividend at a $0.04 per year (one penny per quarter) rate?

Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe?

Pfizer's stock has hit bottom and could see a boost from bird flu fears. Covid-related sales now account for less than 15% of Pfizer's total revenues, de-risking the investment story. Pfizer is cutting $4 billion in annual costs and has raised its EPS target for the year.

Pfizer: Turning The Corner (Rating Upgrade)

Eli Lilly

Vertex Pharmaceuticals

Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.

Got $500? 3 Pharma Stocks to Buy and Hold Forever

Pfizer sells more innovative new medicines than any of its peers. Pfizer has raised its dividend payout every year since 2009.

How Much Will Pfizer Pay Out in Dividends This Year?

Pfizer's revenue and net income are moving in the wrong direction. However, the drugmaker has been rejuvenating its pipeline.

1 No-Brainer Dividend Stock Yielding More Than 5% to Buy and Hold Forever

News for Pfizer Stock (PFE)